NBTX earnings
Nanobiotix S.A. (NBTX) earnings releases and earnings dates - real-time wire coverage of every quarterly report.
Recent earnings items
- NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial ResultsGlobal development program for JNJ-1900 (NBTXR3) proceeded as planned, building toward opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung cancerClinical results reported across multiple tumor types including esophageal cancer, pancreatic cancer, melanoma, head and neck cancer, and lung cancer that supported the broad potential of JNJ-1900 (NBTXR3) across solid tumors treated with radiotherapy next to the completion of the transfer of sponsorship for NANORAY-312Strengthened financial position through the closing of a non-dilutive royalty financing with HealthCare Royalty for up to $71 million and an amendment to the gl
- NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026PARIS and CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, March 31st, 2026, after the close of the U.S. market. This release will be followed by a conference call and webcast on Wednesday, April 1st, 2026, at 8:00 AM EDT / 2:00 PM CEST, prior to the open of the U.S. market. During the call, Laurent Levy, chief executive office
- NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1Data show a favorable safety profile and early efficacy signals in a heavily pre-treated population whose cancer progressed after multiple prior lines of therapy including anti-PD-1Recommended phase 2 dose (RP2D) established at 33% of gross tumor volume (GTV)47.4% (9/19) best observed objective response rate (ORR) in all lesions per RECIST 1.178.9% (15/19) best observed disease control rate (DCR) in all lesions per RECIST 1.114.6 months median Overall Survival (mOS) in all patients treated (n=21)Investigators concluded that these data warrant further investigation in randomized clinical trials as a potential new option for patients with primary cutaneous melanoma naïve or refractory to anti-
- Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic CancerResults demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancerMedian Overall Survival of 23 months from date of diagnosis [95% CI; 17 months – not reached]Median Local Progression-Free Survival of 13.3 months from completion of radiationNotable findings observed in exploratory biomarker analyses include: An association between increased circulating tumor mutational burden (cTMB) and LPFS and OSCA19-9 normalization in 59% of patients in the study, and an association between CA19-9 normalization and OS First patient injected in a new cohort that adds standard-of-care concurre
- Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference CallFull results from the completed dose escalation part and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) after induction chemotherapy for patients with locally advanced or borderline resectable pancreatic cancer to be presented by Principal Investigator Eugene Koay, MD, at ESTRO 2025 on Sunday, May 4th at 11:00 AM EDT / 5:00 PM CESTNanobiotix will host an event on Monday, May 5th at 8:00 AM EDT / 2:00 PM CEST to review the presented results PARIS and CAMBRIDGE, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expa
- NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial ResultsGlobal development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung cancerDisciplined financial strategy toward long-term sustainability and growth continues to strengthen financial position through focused allocation of capital, the receipt of a planned milestone payment, the transfer of sponsorship for NANORAY-312, and an amendment to the global licensing agreement for JNJ-1900 (NBTXR3)Curadigm, a next generation nanotherapeutic platform designed to reshape drug design and development across multiple therapeutic classes and disease areas, has launchedCash r
- NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025PARIS and CAMBRIDGE, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2024, on Wednesday, April 2, 2025, after the close of the U.S. market. This release will be followed by a conference call and webcast on Thursday, April 3, 2025, at 8:00 AM EDT / 2:00 PM CEST, prior to the open of the U.S. market. During the call, Laurent Levy, chief executive officer, a
- NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026PARIS and CAMBRIDGE, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering disruptive nanotherapeutic approaches to revolutionize treatment outcomes for millions of patients, today announced the execution of another disciplined step in its financial strategy through the amendment of the Company's global licensing agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company. The amendment removes Nanobiotix's funding obligation for NANORAY-312 and releases Johnson & Johnson from select future potential milestone payments, while safeguarding Nanobiotix's path to sustainable cashf
- Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 TherapyData show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; "ITT") who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line treatment48% ORR in evaluable anti-PD-1 naïve patients (n=25); 28% ORR in evaluable anti-PD-1 resistant patients (n=25) as per RECIST 1.176% DCR in evaluable naïve patients; 68% DCR in evaluable resistant patients as per RECIST 1.1Preliminary review of survival data in ITT anti-PD-1 naïve patients (n=33) showed mPFS of 7.3 months and mOS of 26.2 monthsITT anti-PD-1 resistant patients (n=35) showed mPFS of 4.2 months and mOS of 7.8 monthsFollowing the ASCO presentation, Nanobiotix wi
- NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference CallNew data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer (n=68) to be presented by Coordinating Investigator Colette Shen, MD, PhD, at ASCO 2024Following the ASCO presentation, Nanobiotix will host an investor event on Sunday, June 2nd at 12:00 PM EDT / 6:00 PM CEST to review the presented results PARIS and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients wit
- NANOBIOTIX Provides First Quarter 2024 Operational and Financial UpdatePARIS and CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided an update on operational progress and reported financial results for the first quarter of 2024. First Quarter Financial Updates Cash and Cash Equivalents: Based on the current operating plan and financial projections, Nanobiotix anticipates that the cash and cash equivalents of €58.9 million as of March 31, 2024, will fund its operations into Q3 2025 which is inclusive of the $20 million milestone we meanwhile received. Conference Call and
- NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024PARIS and CAMBRIDGE, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that it will report its financial and operational results for the first quarter of 2024 on May 22, 2024, before the US and EU markets open. This release will be followed by a conference call and webcast on May 22, 2024 at 8:00 am EDT / 2:00 pm CEST. During the call, Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial officer, will briefly review the Company's first quarter of 2024 results and provide an update on business activ
- NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial ResultsGlobal licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV ("Janssen") expands worldwide potential of novel radioenhancer NBTXR3Prolonged survival in Study 102 reinforces pivotal NANORAY-312 trial design in head and neck cancer; initial efficacy and favorable safety profile supports potential of NBTXR3 in pancreatic cancer; determined RP2D for MD Anderson lung studyMultiple clinical readouts expected in 2024 including immunotherapy combination data from Study 1100, and data from MD Anderson program€75.3 million in cash and cash equivalents as of December 31, 2023 with cash runway into Q3 2025 including the $20 million first development milestone due from
- NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024PARIS and CAMBRIDGE, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that it will report its financial and operational results for the fourth quarter and full year ended December 31, 2023, on Wednesday, April 24, 2024, after the close of the US market. This release will be followed by a conference call and webcast on Thursday, April 25, 2024, at 8:00 am EDT / 2:00 pm CEST before the US market open. During the call, Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial officer, will briefly revi
- NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023PARIS and CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that it will report its financial results for the third quarter ended September 30, 2023, on Monday, November 13, 2023, after the close of the US market. This release will be followed by a conference call and webcast on Tuesday, November 14, 2023, at 8:00 AM ET / 2:00 PM CET. During the call, Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial officer, will briefly review the Company's operational progress, provide an upda
- Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 MonthsFinal data from Study 102 Dose Expansion show that radiotherapy-activated NBTXR3 was feasible and well tolerated in elderly patients with a high burden of comorbidity (n=56)Consistently high injected-lesion overall response rate of 81.8% and complete response rate of 63.6% in the evaluable population (n=44)Median duration of response in the NBTXR3-injected lesion was not reached, suggesting durable anti-tumor efficacyMedian Progression Free of 16.9 months in the evaluable population per independent review committee at the final readoutMedian Overall Survival was 23.1 months in the evaluable population at the final readoutCompared with historical data in a similar population showing mPFS of 9
- NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation OncologyPARIS and CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the oral presentation of the final readout on primary objectives from Study 102 Dose Expansion—the expansion part of a Phase 1 dose escalation and dose expansion study evaluating potential first-in-class radioenhancer NBTXR3 for elderly patients with locally advanced head and neck cancer—at the 65th Annual Meeting of the American Society for Radiation Oncology (ASTRO). These data have also been selected for inclusion in two scientific highlight sess
- NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV ("Janssen") expands worldwide potential of novel radioenhancer NBTXR3Upfront payment and first equity tranche received by Nanobiotix post H1 2023 from agreement with Janssen extends cash runway into the first quarter of 2024 and second quarter if the cash covenant of the European Investment Bank (EIB) was not applicableBolstering of clinical oncology development and commercialization capabilities with appointment of Louis Kayitalire, MD as chief medical officer (CMO)Final Phase 1 safety and efficacy data in head and neck cancer, and initial Phase 1 dose escalation data in pancreatic cancer for NBT
- NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3PARIS and CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced a global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV ("Janssen"), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the investigational, potential first-in-class radioenhancer NBTXR3. NBTXR3 is currently being evaluated in several studies across solid tumor indications including NANORAY-312, a global Phase 3 pivotal study evaluating NBTXR3 for the treatment of patients with locally adv
- NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial ResultsPivotal Phase 3 trial NANORAY-312 ongoing globally with 104 sites activated in 25 countries to date; interim efficacy analysis after 67% of planned progression free survival (PFS) events expected in H2 2024, as plannedFinal data from Study 102 in head and neck cancer expected in H2 2023First pancreatic cancer data expected from MD Anderson trial in H2 2023Chief Medical Officer with strategically aligned multidisciplinary experience in oncology expected to join the company in Q3 2023Reported €41.4 million in cash and cash equivalents as of December 31, 20222022 Universal Registration Document filed with the French financial market authority and the 2022 Annual Report on Form 20-F filed with t
- NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023Conference Call and Webcast to be Held at 2:00 PM CEST/8:00 AM EDT on April 25, 2023 PARIS and CAMBRIDGE, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announces it will issue its financial results for full-year ending December 31, 2022 and provide an operational update, on Monday, April 24, 2023, after the close of the US market. This release will be followed by a conference call and live audio webcast on Tuesday, April 25, 2023, at 2:00 PM CEST/8:00 AM EDT, prior to the open of the US market. During the call, Laurent Lev
- Nanobiotix to Postpone Full Year 2022 Financial Results and Conference CallPARIS and CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the company will postpone the release of its full year financial results initially scheduled for Tuesday, March 28, 2023 at 4:15 p.m. EDT and conference call initially scheduled for Wednesday, March 29, 2023. The company will announce its full year 2022 financial results and conference call schedule in a future press release to allow additional time to complete its year-end closing procedures. About NANOBIOTIX: Nanobiotix is a late-stage clin
- Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023Conference Call and Webcast to be Held at 2:00 P.M CET/8:00 A.M. EDT on March 29, 2023 PARIS and CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announces that it will provide an operational update and report its financial results for full-year ending December 31, 2022, on Tuesday, March 28, 2023, after the close of the US market. This release will be followed by a conference call and live audio webcast on Wednesday, March 29, 2023, at 2:00 PM CET/8:00 AM EDT, prior to the open of the US market. During the call,
- NANOBIOTIX Reports Updated Phase 1 Anti-PD-1 Combination Data That May Support the Immune Stimulation Potential of Radioenhancer NBTXR3 at the 37th Annual Meeting of the Society for Immunotherapy of CancerData show that radiotherapy-activated NBTXR3 followed by anti-PD-1 was feasible and well tolerated in the complete dose escalation part of the Company's phase 1 immunotherapy study with a recommended phase 2 dose established at 33% of gross tumor volume in all 3 cohortsResults include 5 additional patients of 21 evaluable as of the data cutoff on 22 August 2022 and continue to suggest local control and immune stimulation regardless of prior anti-PD-1 exposureObjective reduction from baseline in all target lesions ("objective reduction") was observed in 71.43% of evaluable patients (15/21) and objective reduction of more than 30% was observed in 42.86% of evaluable patients (9/21)Objective re
- NANOBIOTIX Provides Third Quarter 2022 Operational and Financial UpdateEstablished recommended Phase 2 dose (RP2D) for NBTXR3 plus anti-PD-1 in patients with locoregional recurrent and recurrent and/or metastatic head and neck cancer, lung metastases from any primary tumor, or liver metastases from any primary tumorUpdated Phase 1 NBTXR3 plus anti-PD-1 safety and efficacy data in recurrent and/or metastatic advanced cancers from Study 1100 to be presented at SITC 2022 on November 10thBolstered NBTXR3 strategic development capability with the appointment of twelve global medical experts to the Nanobiotix Scientific Advisory Board€53.5 million in cash and cash equivalents extends cash runway into Q1 2024 PARIS and CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIR
- NANOBIOTIX to Announce Third Quarter 2022 Financial Results on November 9, 2022PARIS and CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will report its financial results for the third quarter ended September 30, 2022, on Wednesday, November 9, 2022, after the close of the US market. The announcement will be followed by a conference call and live audio webcast on Thursday, November 10, 2022, at 8:00 AM ET / 2:00 PM CET. During the call, Laurent Levy, chief executive officer, and Bart Van Rhijn, chief financial officer, will briefly review the Company's third quarter results a
- Nanobiotix Provides Business Update and Reports Financial Results for the First Half of 2022Pivotal Phase 3 study, NANORAY-312, actively enrolling elderly, LA-HNSCC patients ineligible for cisplatin across ~50 sites as LianBio enrolls first patient and continues to ramp up site activation in Asia and Nanobiotix adds European sites, and begins recruitment in the US Recommended Phase 2 dose for I/O combination Study 1100 determined and cohorts in dose expansion phase aligned with planned registration pathway for NBTXR3 plus anti-PD-1 for patients suffering from treatment-resistant recurrent/metastatic head and neck squamous cell carcinoma Reported €63.0 million in cash and cash equivalents as of June 30, 2022 which, combined with proposed EIB debt restructuring and existing e
- Nanobiotix to Announce Half Year 2022 Financial Results on September 28, 2022Conference Call and Webcast to be Held at 8:00 AM ET / 2:00 PM CET on September 29, 2022 Regulatory News: NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will report its financial results for half-year ending June 30, 2022, on Wednesday, September 28, 2022, after the close of the US market. The announcement will be followed by a conference call and live audio webcast on Thursday, September 29, 2022, at 8:00 AM ET / 2:00 PM CET. During the call, Laurent Levy, chief executive officer, and Bart Van Rhijn, chief financial officer, will briefly review t
- CORRECTING and REPLACING: NANOBIOTIX Provides First Quarter Operational and Financial UpdateOn-track to activate first US clinical trial sites in on-going pivotal phase III global registration study, NANORAY-312, in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) in Q3 2022 Received preliminary feedback from FDA informing development of pivotal Phase III protocol for NBTXR3 in combination with anti-PD-1 therapy, protocol submission planned in Q1 2023 Cash position totaling €70.6 million as of March 31, 2022 Prioritizing research and development programs to reduce operating expenses and establishing flexible equity financing line that can be accessed at the Company's discretion to extend operating runway into Q4 2023 Exploring broader debt restructuring t
- NANOBIOTIX Provides First Quarter Operational and Financial UpdateOn-track to activate first US clinical trial sites in on-going pivotal phase III global registration study, NANORAY-312, in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) in Q3 2022 Received preliminary feedback from FDA informing development of pivotal Phase III protocol for NBTXR3 in combination with anti-PD-1 therapy, protocol submission planned in Q1 2023 Cash position totaling €70.6 million as of March 31, 2022 Prioritizing research and development programs to reduce operating expenses and establishing flexible equity financing line that can be accessed at the Company's discretion to extend operating runway into Q4 2023 Exploring broader debt restructuring t
- NANOBIOTIX to Announce First Quarter 2022 Financial Results on May 18, 2022Regulatory News: NANOBIOTIX (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will report its financial results for the first quarter of 2022 ending March 31, 2022, on Wednesday, May 18, 2022, after the close of the US market. The announcement will be followed by a conference call and live audio webcast on Thursday, May 19, 2022, at 8:00 AM EDT / 2:00 CET, prior to the opening of the US market. During the call, Laurent Levy, chief executive officer, and Bart Van Rhijn, chief financial officer, will briefly review the Company's first quarter results and provide a
- NANOBIOTIX Provides Business Update and Reports Full Year 2021 Financial ResultsNew data from Expansion Study 102 in high-risk, LA-HNSCC patients highlights potential clinical benefit of NBTXR3 showing a median Overall Survival reaching 23 months in evaluable patients; Data with minimum follow-up of one year for full study population anticipated in mid-2023 Pivotal Phase III study, NANORAY-312, now actively enrolling elderly, LA-HNSCC patients ineligible for cisplatin across multiple European sites with US site activation anticipated in mid-2022 Expansion Phase to be added to Study 1100 evaluating NBTXR3 in combination with anti-PD-1 therapy in three cohorts, including two cohorts focused on R/M HNSCC patients that are either naïve to anti-PD-(L)-1 therapy or resi
- NANOBIOTIX to Announce Full Year 2021 Financial Results on March 30, 2022Conference Call and Webcast to be Held at 8:00 A.M. EDT/2:00 P.M CET on March 31, 2022 NANOBIOTIX (NASDAQ:NBTX) (PARIS:NANO) (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announces that it will report its financial results for full-year ending December 31, 2021, on Wednesday, March 30, 2022, after the close of the US market. The announcement will be followed by a conference call and live audio webcast on Thursday, March 31, 2022, at 8:00 AM EDT / 2:00 PM CET, prior to the open of the US market. During the call, Laurent Levy, chief executive officer, and Bart Van Rhijn, chief
- NANOBIOTIX Provides Business Update and Reports Financial Results for the First Half of 2021Positive data from Study 102 Expansion reported in H1 2021 included an overall objective response rate of 82.5% and a complete response rate of 62.5% in highly vulnerable, elderly patient population, providing continued support for the planned initiation of a pivotal phase III global registration study in locally advanced head and neck squamous cell carcinoma in late Q4 2021 Following positive data from ongoing Study 1100 presented in H1 2021 showing that NBTXR3 in combination with anti-PD-1 resulted in tumor regression in 76.9% of evaluable patients regardless of prior anti-PD-1 exposure, Nanobiotix intends to initiate discussions with regulatory authorities in H2 2021 regarding the pot